Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score

Rheumatology (United Kingdom)

Volumn 53, Issue 7, 2014, Pages 1229-1234

  Horneff, Gerd ^a   Becker, Ingrid ^b  

^a Centre of Paediatric Rheumatology Department of General Paediatrics Asklepios Clinic Sankt Augustin   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ACR; Definition of improvement; JADAS; Juvenile idiopathic arthritis; Response parameters

Indexed keywords

ADALIMUMAB; ETANERCEPT; METHOTREXATE;

ACCURACY; ADOLESCENT; ARTICLE; CHILD; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG EFFICACY; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ACR; DEFINITION OF IMPROVEMENT; JADAS; JUVENILE IDIOPATHIC ARTHRITIS; RESPONSE PARAMETERS;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; MALE; METHOTREXATE; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84902992477     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket470     Document Type: Article

References (18)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
2. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
3. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138-49.
4. Consolaro A, Ruperto N, Bazso A et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Care Res 2009;61: 658-66.
5. Freudenhammer K. Simplification of apparatus used in the Westergreen method of determination of blood sedimentation. Medizinische 1956;18:260.
6. Horneff G, Schmeling H, Biedermann T et al. The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2004;63:1638-44.
7. Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68: 519-25.
8. Horneff G, Foeldvari I, Minden K et al. 10 years experience in the German JIA Etanercept Registry - lessons from changing patient populations. Arthritis Rheuma 2011;31: 334-42.
9. Horneff G, Niehues T, Huppertz HI et al. Response to etanercept in juvenile idiopathic arthritis using the continuous measure Juvenile Arthritis Disease Activity Score (JADAS). Ann Rheum Dis 2012;71(Suppl 3):431.
10. Ravelli A, Viola S, Migliavacca D et al. Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. Rheumatology 2001;40:914-9.
11. Nordal EB, Zak M, Aalto K et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis 2012;71:1122-7.
12. Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009;10:3049-60.
13. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
14. Wallace CA, Giannini EH, Huang B et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63: 929-36.
15. Wallace CA, Giannini EH, Spalding SJ et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
16. Beukelman T, Patkar NM, Saag KG et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63:465-82.
17. Consolaro A, Bracciolini G, Ruperto N et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012;64:2366-74.
18. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twentyeight- joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44-8.